Halozyme Therapeutics (HALO) Insider Krishnan Buys $281K of Stock
Mahesh Krishnan purchased 7,304 shares of Halozyme Therapeutics on June 29.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mahesh Krishnan bought 7,304 shares of Halozyme Therapeutics, Inc. ($HALO) at an average price of $38.46, worth about $280,911.84, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $HALO is up 4.7% after 1 week, up 7.9% after 1 month and up 57.9% to date (from the $77.18 close on Jun 29, 2026).
HALO
Halozyme Therapeutics, Inc.
Key Points
- On June 29, 2026, Mahesh Krishnan bought 7,304 shares of Halozyme Therapeutics (HALO) at a price of $38.46 each, totaling approximately $280,912.
- Halozyme's stock was recently priced at $78.27, significantly higher than Krishnan's purchase price, suggesting potential upside.
- The company's next earnings report is expected on November 2, 2026, following a period of solid revenue growth.
Get $HALO trade alerts by text
We text you when insiders, Congress or big funds trade $HALO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Halozyme Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Halozyme Therapeutics, Inc.
On June 29, 2026, Mahesh Krishnan bought 7,304 shares of Halozyme Therapeutics, Inc. (HALO) at $38.46 each, amounting to about $280,912. This transaction indicates Krishnan's confidence in the company, especially considering he is acquiring shares at a lower price compared to the recent market price.
Stock Performance Context
The shares of Halozyme are currently trading at $78.27, well above Krishnan's purchase price. This suggests that his buy could be seen as a strategic move, taking advantage of a lower entry point in a stock that has room to grow, especially given the company's market dynamics.
Analysts Set New Price Targets
Recent analyst ratings show a generally positive outlook for Halozyme. On October 13, 2026, TD Cowen maintained a "Buy" rating with a price target of $130, up from a previous target of $105. JP Morgan also maintained a "Neutral" rating with a target increased to $78 from $70 on October 8, 2026. These insights suggest analysts expect the stock to perform well, which aligns with Krishnan's recent purchase.
What Halozyme Therapeutics, Inc. Does
Halozyme Therapeutics focuses on biopharmaceuticals, developing innovative enzymes and devices. Its products facilitate the delivery of various therapeutic treatments, and the company has a strong market presence, particularly in oncology.
What to Watch at Halozyme Therapeutics, Inc.
Investors will be looking forward to Halozyme's earnings report set for November 2, 2026, to gauge its performance and outlook. Additionally, Krishnan's recent purchase adds to the narrative of insider confidence in the company's future growth potential.
Related Filing Alerts
Source: Mahesh Krishnan's Form 4 filing on $HALO (Jun 29, 2026). Find the original filing: HALO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts